FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120304834> ?p ?o ?g. }

• W3120304834 endingPage "S102" @default.
• W3120304834 startingPage "S102" @default.
• W3120304834 abstract "Abstract Background Levofloxacin prophylaxis in pediatric oncology patients with chemotherapy-induced severe prolonged neutropenia has been shown to reduce risk for febrile neutropenia and systemic infections. With increased use of prophylaxis there is concern for development of antibiotic-resistant infections. We analyzed bloodstream infections (BSI) in pediatric oncology patients exposed to levofloxacin prophylaxis during prolonged severe neutropenic episodes to determine the rate of antibiotic resistance Methods We performed a retrospective chart review of pediatric oncology patients who received levofloxacin prophylaxis between January 2015 – December 2019. Patients were placed on levofloxacin prophylaxis based on institutional guidelines for patients at risk for severe prolonged neutropenia (i.e., absolute neutrophil count [ANC] &lt; 500 cells/µL for &gt;7 days). Demographic information, start and end dates for levofloxacin prophylaxis, and all BSI episodes within 2 months after exposure to the fluoroquinolone were collected Results Thirty-five patients were identified who received levofloxacin prophylaxis. There were 32 BSI in 12 patients. Twenty-five BSI involved gram-positive organisms (GP), including nine (36%) due to coagulase negative Staphylococcus and seven (28%) due to viridans Streptococcus. Seven BSI episodes involved gram-negative (GN) organisms with 4 (57%) from E.coli. Resistance to fluroquinolones was noted in 42% and 48% of BSI from GN and GP organisms respectively. The vast majority (85%) of viridans Streptococcus isolates were resistant to levofloxacin. In contrast, 8% of viridans Streptococcus isolates were resistant to fluoroquinolones from the same time frame per our hospital antibiogram. Conclusion In this recent cohort of pediatric oncology patients with BSI after exposure to levofloxacin prophylaxis, there was a high percentage infected with fluoroquinolone-resistant organisms.This contrasts with some of the earlier published data from adults which reported low rate of fluoroquinolone resistance. This case series highlights the need for close monitoring for development of antibiotic resistance as utilization of prophylactic levofloxacin increases in pediatric oncology patients. Disclosures All Authors: No reported disclosures" @default.
• W3120304834 created "2021-01-18" @default.
• W3120304834 creator A5007078872 @default.
• W3120304834 creator A5033220689 @default.
• W3120304834 creator A5040045104 @default.
• W3120304834 creator A5063797922 @default.
• W3120304834 creator A5072679208 @default.
• W3120304834 date "2020-10-01" @default.
• W3120304834 modified "2023-09-26" @default.
• W3120304834 title "194. Antibiotic-resistant bloodstream infections in pediatric oncology patients on levofloxacin prophylaxis" @default.
• W3120304834 doi "https://doi.org/10.1093/ofid/ofaa439.238" @default.
• W3120304834 hasPublicationYear "2020" @default.
• W3120304834 type Work @default.
• W3120304834 sameAs 3120304834 @default.
• W3120304834 citedByCount "0" @default.
• W3120304834 crossrefType "journal-article" @default.
• W3120304834 hasAuthorship W3120304834A5007078872 @default.
• W3120304834 hasAuthorship W3120304834A5033220689 @default.
• W3120304834 hasAuthorship W3120304834A5040045104 @default.
• W3120304834 hasAuthorship W3120304834A5063797922 @default.
• W3120304834 hasAuthorship W3120304834A5072679208 @default.
• W3120304834 hasBestOaLocation W31203048341 @default.
• W3120304834 hasConcept C126322002 @default.
• W3120304834 hasConcept C2776694085 @default.
• W3120304834 hasConcept C2777063308 @default.
• W3120304834 hasConcept C2778602436 @default.
• W3120304834 hasConcept C2778850193 @default.
• W3120304834 hasConcept C2779443120 @default.
• W3120304834 hasConcept C2781276175 @default.
• W3120304834 hasConcept C501593827 @default.
• W3120304834 hasConcept C71924100 @default.
• W3120304834 hasConcept C86803240 @default.
• W3120304834 hasConcept C89423630 @default.
• W3120304834 hasConceptScore W3120304834C126322002 @default.
• W3120304834 hasConceptScore W3120304834C2776694085 @default.
• W3120304834 hasConceptScore W3120304834C2777063308 @default.
• W3120304834 hasConceptScore W3120304834C2778602436 @default.
• W3120304834 hasConceptScore W3120304834C2778850193 @default.
• W3120304834 hasConceptScore W3120304834C2779443120 @default.
• W3120304834 hasConceptScore W3120304834C2781276175 @default.
• W3120304834 hasConceptScore W3120304834C501593827 @default.
• W3120304834 hasConceptScore W3120304834C71924100 @default.
• W3120304834 hasConceptScore W3120304834C86803240 @default.
• W3120304834 hasConceptScore W3120304834C89423630 @default.
• W3120304834 hasIssue "Supplement_1" @default.
• W3120304834 hasLocation W31203048341 @default.
• W3120304834 hasLocation W31203048342 @default.
• W3120304834 hasLocation W31203048343 @default.
• W3120304834 hasOpenAccess W3120304834 @default.
• W3120304834 hasPrimaryLocation W31203048341 @default.
• W3120304834 hasRelatedWork W1525555991 @default.
• W3120304834 hasRelatedWork W2107035784 @default.
• W3120304834 hasRelatedWork W2254822967 @default.
• W3120304834 hasRelatedWork W2276446263 @default.
• W3120304834 hasRelatedWork W2530257110 @default.
• W3120304834 hasRelatedWork W2562099349 @default.
• W3120304834 hasRelatedWork W2884532732 @default.
• W3120304834 hasRelatedWork W3091497408 @default.
• W3120304834 hasRelatedWork W3100107808 @default.
• W3120304834 hasRelatedWork W3120304834 @default.
• W3120304834 hasVolume "7" @default.
• W3120304834 isParatext "false" @default.
• W3120304834 isRetracted "false" @default.
• W3120304834 magId "3120304834" @default.
• W3120304834 workType "article" @default.